Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.
The aim of this retrospective study was to compare concurrent radiation therapy (RT) combined with peroral chemotherapy (UFT or TS-1) with conventional RT for T2N0 glottic cancer. Between 1974 and 2005, 153 patients with T2N0 glottic cancer were treated with radiation alone or radiation combined with peroral (UFT or TS-1) or intravenous chemotherapy. All except one patient were treated with 2 Gy per fraction, 5 fractions per week, totaling 60 Gy; and the remaining patient was treated with 1.8 Gy per fraction, 5 fractions per week, totaling 61.2 Gy. Eighty-three patients were concurrently given UFT, 24 were given TS-1, 23 intravenous chemotherapy (mainly cisplatin; the Pt Group), and 23 had no chemotherapy. The 5-year local control rate was 83.4%. Stratified by RT alone (the RT group) and concurrent chemoradiation therapy (the CCRT group), 5-year local control rates of the RT and CCRT groups were 82.7% and 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of the CCRT group, 3-year local control rates of the UFT, TS-1 and Pt groups were 90.1%, 100.0% and 73.4%, respectively. Concurrent chemoradiation therapy using UFT or TS-1 for T2N0 glottic cancer is one of the standard treatments in Japan. Concurrent use of TS-1 could be a breakthrough treatment for T2N0 glottic cancer.
Niibe
Yuzuru
Y
Department of Radiology, Kitasato University School of Medicine, Kanagawa, Japan. joe-n@hkg.odn.ne.jp
Nakayama
Meijin
M
Matsubayashi
Takashi
T
Takahashi
Hiroomi
H
Kitano
Masahi
M
Okamoto
Makito
M
Hayakawa
Kazushige
K
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007564:Japan; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017640:Silicates / Q000627:therapeutic use*; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use*; D014025:Titanium / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D017640:Silicates; C103828:titanium silicide; D005641:Tegafur; D014025:Titanium